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ABSTRACT 
 
The goal of infection control is to minimize the risk of exposure to potential pathogens 
and to create a safe working environment in which patients can be treated. Use of 
disinfectants in is an integral part of infection control. The rate of killing of 
microorganisms depends upon the type, concentration and time of exposure of the killing 
agent (disinfectant). Chlorinated compounds are frequently used in healthcare settings but 
chlorine dioxide has only been used in industries on a large scale. Aseptrol® is newly 
developed slow release chlorine dioxide and noncorrosive formula which can be used on 
a smaller scale basis. This study assessed the antimicrobial properties of Aseptrol® 
(48ppm and 24ppm) in comparison with previously used sodium dichloroisocyanurate 
containing formula, Presept® (10 000ppm).  
 
Both disinfectants killed more susceptible bacteria, such as Staphylococcus aureus,  
Pseudomonas. aeruginosa and Streptococcus mutans within 30 seconds and proved to be 
fungicidal by killing Candida albicans within 30 seconds. Aseptrol® and Presept® killed 
less susceptible mycobacteria such as Mycobacterium tuberculosis, Mycobacterium 
avium subsp. avium and blood borne organism Hepatitis B virus within 30 seconds. 
Highly resistant B. subtilis spores were killed in 2 and 2.5 minutes by Aseptrol® and 
Presept® respectively.  
 
Although manufacturers recommend that the disinfectant solutions should be prepared 
daily, when the shelf-life of prepared solutions stored in screw cap bottles was studied, 
the results showed that Aseptrol® can be effectively used for 27 day and Presept® for 
more than 37 days.   
 
 v
Chlorinated disinfectants, such as Aseptrol® and Presept®, have potential to be used as  
intermediate to high level disinfectants in medical and dental settings, where above test 
organisms are primary contaminants. It is also possible to use them as sterilants, where 
semicritical conditions are required. Aseptrol® has an additional advantage because it is 
noncorrosive and can be used on metal instruments. 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
 
1.1 INTRODUCTION 
 
Health care personnel are constantly exposed to wide variety of pathogenic 
microorganisms that can cause infections. Many microorganisms are transmitted in 
medical and dental hospitals including Escherichia coli, Staphylococcus aureus, 
Pseudomonas aeruginosa, Candida species, Mycobacteria, Hepatitis viruses and Human 
immunodeficiency virus (HIV) (Mims et al., 2004). Infection control is an integral part of 
patient care and hospital setting in order to prevent nosocomial infections (Larson EL, 
1995). The goal of infection control is to minimize the risk of exposure to potential 
pathogens and to create a safe working environment in which patients can be treated. 
Disinfection is a process of removing or killing most, but not all, viable microorganisms. 
Sterilization and Disinfection are key processes in the control and prevention of hospital 
acquired infections, as well as being central to many areas of medical practice. 
Disinfectants containing chlorines, aldehydes, phenols, alcohols and heavy metals are 
available and regularly used in the hospital environment (McDonnell and Russell, 1999) 
and they all have advantages and disadvantages.  
 
The rate of killing of microorganisms depends upon the type, time of exposure and the 
concentration of the killing agent. Efficacy of disinfectants is routinely tested against 
standard indicator microorganisms (Rutala et al., 2000, Brady et al., 2003, Raffo et al., 
2007, Taylor et al., 1999). This study was undertaken to establish efficacy of two chlorine 
based disinfectants in a laboratory environment. 
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1.2 LITERATURE REVIEW 
 
1.2.1 Nosocomial infections 
 
Centre for Disease Control (CDC) defines nosocomial infections as a localized or 
systemic condition resulting from an adverse reaction to the presence of an infectious 
agent(s) or its toxin(s), without any evidence that the infection was present or incubating 
at the time of admission to the acute care setting (Garner et al., 1988). It occurs 48 hours 
or more after admission and up to 48 hours after the patient has been discharged. 
Nosocomial infections can occur due to endogenous or exogenous source. Exogenous 
source is usually another patient, hospital environment and healthcare workers. The 
common nosocomial infections are surgical wound infections, respiratory tract infections, 
urinary tract infections and bacteraemia. They constitute a major fraction of the adverse 
events complicating hospital treatments and are critical threat to patients, especially in the 
Intensive Care Unit (Kampf et al., 1998). Patients treated in intensive care units (ICUs) 
are at increased risk to acquire such infections because the invasive devices, such as 
mechanical ventilators, catheters, often used in these patients create ports of entry for 
opportunistic bacteria and fungi (Gastmeier, 2004).  
 
Ding et al., (2009) reported a high and relatively stable rate of nosocomial infections in 
the ICU of a tertiary hospital in China through year 2003–2007, with some differences in 
the distribution of the infection sites. The sources of these infectious agents are patients, 
healthcare workers and objects. The route of transmission is air, droplets, direct contacts, 
devices, food, blood products and intravenous (IV) fluids.  
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The consequences of hospital infections are serious illness and death, prolonged hospital 
stay (meaning increased cost), additional treatment with antimicrobials (meaning cost, 
drug toxicity and increased risk of development of resistance), and infected patient 
becomes a risk and a source of infection. 
 
Prevention of hospital infections can be done by excluding the source of infection from 
the hospital environment, interrupting the transmission of infection from source to 
susceptible host and enhancing the host’s ability to resist infection (Mims et al., 2004). 
Transmission interruption can be achieved by establishing infection control in the 
hospital. One of the key aspects of infection control is use of disinfectants. 
 
1.2.2 Infection control in medical healthcare settings 
 
There are standard precautions for health-care workers (HCWs) presented by Centre for 
Disease Control (CDC). These guidelines are step by step infection control measures that 
should be followed by health-care professionals. They describe hand washing, protective 
barriers, sterilization and disinfection, waste disposal and accidental injuries. Although 
requirement of hand washing was known as early as 1822, first CDC guidelines for hand 
washing were published in 1975 and 1985 (Steere and Mallison, 1975; Garner and Favero, 
1986). Surgical procedures, blood transfusion, and frequent visits to different dialysis 
units are major risk factors for contracting viral hepatitis. The results of Karkar et al., 
(2006) clearly showed that isolation of patients and machines, together with strict 
adherence to infection control policies and procedures, result in a significant decline in the 
incidence and prevalence and better control of viral hepatitis transmission among 
haemodialysis patients. Infections have been linked to endoscopic procedures due to 
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inadequate cleaning and disinfection during the reprocessing of the instruments and their 
accessories (Nelson, 2003; Lisgaris, 2003). In hospitals, environmental contamination has 
been linked to transmission of some important nosocomial pathogens, including 
methicillin-resistant Staphylococcus aureus (Mulligan et al., 1993), vancomycin-resistant 
Enterococcus species (Bonten et al., 1996), and Clostridium difficile (Malamou-Ladas et 
al., 1983). 
 
1.2.3 Infection control in dental healthcare settings 
 
Dental care is a field of high priority regarding the risk of infections. The dentist has to 
consider every patient potentially infected. On the other hand, health-care workers are not 
only susceptible persons to infections but they can also be sources of infections. In order 
to prevent the nosocomial infections, the dentist has to ensure the hygienic protection of 
both the patients and the health-care workers. All the health-occupational measures have 
to be known and kept by the dental personnel. The health personnel have to be informed 
of the risk and how to prevent infections. The essential importance of hygiene, the role of 
protective equipment and all the duties connected with should be emphasized. 
 
Dental patients and health-care workers may be exposed to a variety of microorganisms 
by dental instruments or by direct contact with blood or respiratory secretions. The most 
likely mode of transmission is droplets from infected patients. Typical contaminating 
microorganisms include Cytomegalovirus, Hepatitis B virus (HBV), Hepatitis C virus 
(HCV), Herpes simplex virus types 1 and 2, HIV and Mycobacterium tuberculosis. 
Pathogens may be transmitted by direct contact with blood, oral fluids, or other secretions; 
indirect contact with contaminated instruments, operatory equipment, or environmental 
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surfaces; or contact with airborne contaminants present in droplets. The precautionary 
measures are similar to medical settings except protective barriers are very important due 
to the aerosols that are created by the procedures. Use of disinfectant is similar in both 
setting. CDC has presented guideline for infection control in dentistry (Kohn et al., 2003) 
describing above measures. 
 
The frequency of exposure to HBV is greater in dental care workers (Naqao et al., 2008). 
Hepatitis B infection is a significant hazard in the dental environment because the virus 
may be transmitted through contaminated dental instruments such as hand pieces (Deng et 
al., 2005). Several studies have shown that even low-level disinfectants are able to kill 
HBV, Hepatitis C virus (HCV) and HIV (Bond et al., 1983; Prince et al., 1993). 
Radiographic films can be another source of infections. A study done by Coogan et al., 
(2004) has shown that Presept, a sodium dichloroisocyanurate based disinfectant, can be 
effective in the disinfection of radiographic films and gloves. Dental impressions are also 
potential transmission routes for pathogenic microorganisms that infect the oral cavity and 
respiratory tract and chlorine based disinfectants can be effective in decontaminating 
impressions (Rweyendela et al., 2009). Routine disinfection of impressions has been 
recommended to protect clinicians, laboratory personnel and patients (Owen and Goolam, 
1993). 
 
1.2.4 Disinfectants and their role in infection control 
 
Disinfection is a process that eliminates many or all pathogenic microorganisms on 
inanimate objects with the exception of bacterial spores. With prolonged exposure 
however, some disinfectants can kill spores. Disinfectants are often the only practical 
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means of rapidly disinfecting heat sensitive equipments at point of use. A prerequisite for 
a disinfectant is its effectiveness against the expected spectrum of pathogens. To be 
effective, a disinfectant must produce consistently high percentage kill levels on every test 
(Schwartz et al., 1996). Besides the broad spectrum activity, it should be fast acting, 
nontoxic, odourless and easy to use. It should also be active in the presence of organic 
material, leave residual effect, be stable, economically and environmentally friendly.  
 
Disinfectants are selected according to their use in degree or level of contamination, 
which can be categorised as critical, semicritical and noncritical. In the hospital 
environment, all three areas are recognised. Critical category includes surgical 
instruments, cardiac and urinary catheters, implants and ultrasound probes used in sterile 
body cavities. Heat sensitive objects are either treated with ethylene oxide, hydrogen 
peroxide gas plasma or by liquid chemical sterilants. Aldehyde-based agents have been 
commonly used for high-level disinfection in most hospitals. Glutaraldehyde is by far the 
most used, especially for equipments, because of its broad spectrum activity and potency 
(Hernández et al., 2003). However, polymerisation, potential mutagenic and carcinogenic 
effects of glutaraldehyde is problematic (Espigares et al., 2003). Chlorinated compounds 
are corrosive to metals and cause irritation to skin and mucosa (Robinson et al., 1986; 
Zhang et al., 2008). Alcohols do not have broad-spectrum activity (Woo et al., 2002). Use 
of triclosan a phenol based disinfectant to disinfect catheters and vascular grafts, has been 
described by Kim et al., (2002) and Hernández-Richter et al., (2000). 
 
Semicritical items are those that come in contact with mucous membranes or non-intact 
skin. Endoscopes, laryngoscope blades, rectal memometric catheters are some of the 
devices which should be free of all microorganisms but small number of spores can be 
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present. Chemical disinfectants such as glutaraldehyde, hydrogen peroxide can be used for 
this purpose. They should be rinsed with sterile water after disinfection to prevent the 
microbial contamination of tap water.  
 
Noncritical items are those that come in contact with intact skin but not mucous 
membranes. These are bedpans, blood pressure cuffs, bed rails, linens, floors etc., which 
can be decontaminated with low-level disinfectants. Some of the disinfectants are 
described below.  
 
1.2.4.1 Alcohol 
 
Alcohols are bactericidal rather than bacteriostatic and generally kill bacteria in vegetative 
form, fungi, viruses and even mycobacteria but not bacterial spores. Ethyl and isopropyl 
alcohols are the most effective alcohols and they are used in hospital settings. Alcohols 
denature microbial proteins and are most effective at 60 to 90% solution made with water 
(Morton, 1950; Morton 1983; Ali et al., 2001). The use is limited because of the lack of 
penetration into protein-rich material and sporicidal activity.   
 
1.2.4.2  Formaldehyde and Glutaraldehyde 
 
Formaldehyde is used as a disinfectant and sterilant both in liquid and gaseous form. The 
aqueous solution is bactericidal, mycobactericidal, viricidal, fungicidal and sporicidal 
(Klein and Deforest, 1963; Rubbo et al., 1967). The use of formaldehyde is limited due to 
its carcinogenic property (OSHA, 1991), irritating fumes and the pungent odour.  
 
 8
Glutaraldehyde is a saturated dialdehyde used as a high-level disinfectant and chemical 
sterilant. It has an excellent biocidal activity even in the presence of organic material and 
it is noncorrosive. It is widely used in healthcare facilities to sterilize endoscopes, 
thermometers and rubber or plastic equipments. In dentistry, it is extensively used. 
Glutaraldehyde causes alkylation of sulfhydral, hydroxyl, carboxyl and amino groups of 
microorganisms, which alters ribonucleic acid (RNA), deoxyribonucleic acid (DNA) and 
protein synthesis (Scott and Gorman, 2001). However there are reports showing 
glutaraldehyde resistant mycobacteria such as M. chelonae, M. intracellulare (van 
Klingeren and Pullen, 1993; Griffiths et al., 1997) and some fungi (Barbee et al., 1999). 
 
1.2.4.3 Iodine and Iodophors 
 
Iodine has been used as an antiseptic for years by health professionals. Iodophor is a 
combination of iodine and a solubilizing agent or carrier. The combination is more stable 
with sustained release of iodine, free of toxicity, irritancy and non-staining property. 
Iodine is able to penetrate the cell wall of microorganisms quickly and the lethal effect is 
due to the disruption of protein and nucleic acid structure and synthesis. Iodophors are 
bactericidal, mycobactericidal, viricidal but may require prolonged contact times to kill 
certain fungi and spores (Klein and de Forest, 1963; Sattar et al., 1983; Rutala et al., 
1991). In dentistry, iodine is used as mouthrinse effectively to reduce plaque and 
gingivitis (Domingo et al., 1996; Maruniak et al., 1992). 
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1.2.4.4 Chlorine and chlorine compounds 
 
Chlorine-releasing agents are well established as environmental disinfectants. 
Hypochlorites are the most widely used compounds and they are available in liquid or 
solid form. The most used chlorine compound is sodium hypochlorite, which is usually 
called household bleach. It has broad spectrum antimicrobial activity, does not leave toxic 
residues, is unaffected by water hardness, fast acting, inexpensive, removes dried or fixed 
microorganisms and biofilms from surfaces. The disadvantages are: it is inactive in the 
presence of organic matter, corrosive to metals, eye and skin irritant and relatively 
unstable.  
 
Alternative compounds that release chlorine and are used in the healthcare setting include 
demand-release chlorine dioxide, sodium dichloroisocyanurate and chloramine T. These 
compounds retain chlorine longer, meaning they have prolonged bactericidal effect.  
 
Chlorine dioxide (ClO2), which is a gas at temperature above 11oC, has long been known 
to have germicidal properties (Chen and Vaughn, 1990; Farr and Walton, 1993; Eleraky et 
al., 2002; Wilson et al., 2005) and has been used in large scale municipal and industrial 
water purification and wastewater treatment system. It is a water-soluble gas and exhibits 
rapid kill over a wide range of organisms. It works through oxidation and penetrates 
bacterial cell walls and reacts with vital amino acids in the cytoplasm of the cell to kill the 
organism. Chlorine dioxide has been proven to kill a diverse array of bacteria, viruses, 
algae, fungi and protozoa. It has a long history of use as a disinfectant and is accepted by 
the United States Environmental protection agency (EPA) drinking water division in 
water treatment applications. Compared to phenols, bleach, glutaraldehyde, quaternary 
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ammonium compounds and other disinfectants, it is the most effective biocide on hard 
surfaces (Tanner, 1989) and has been shown to have a degree of fungicidal and sporicidal 
activity in solution (Price and Ahearn, 1999; Weaver-Meyers et al., 2000).  
Chlorine dioxide water treatment system is safe and efficient in controlling Legionella 
contamination of hospital water supplies (Srinivasan et al., 2003; Zhang et al., 2007). 
 
Chlorine dioxide offers a variety of safety and environmental advantages over chlorine 
and many other commonly used antimicrobial agents and is four to seven times more 
effective as a biocide than chlorine at equivalent doses. Furthermore, it does not produce 
halogenated, carcinogenic by-products, such as trihalomethanes, dioxins and haloacetic 
acids, which may be produced when free chlorine is used. It maintains its efficacy over a 
wide pH range (1-10) while chlorine’s effectiveness is significantly reduced above neutral 
or basic pH.  
.  
The use of chlorine dioxide had previously been restricted to large-scale industrial 
applications because it could not be incorporated into a stable, easy-to-use powder and 
tablet form. The development of new delivery technology (Engelhard Aseptrol 
technology) that allows chlorine dioxide to be generated at the point of use, in smaller 
quantities, without special equipments, has opened the door for smaller scale uses. 
Aseptrol® is unreactive in dry form but produces chlorine dioxide only when exposed to 
moisture in ambient temperature or dissolved in water. When sealed in airtight containers, 
it can be stored and used when needed (Cochran M, 2005). The formula of Aseptrol®, 
incorporates stabilizing agents and anticorrosion compounds making them suitable for 
small-scale applications. The manufacturer of this product claims of numerous advantages 
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of usage in industrial setting. The efficacy of Aseptrol® in medical and dental hospitals 
has not been established.   
 
Sodium dichloroisocyanurate (NaDCC) is a stable source of chlorine (Janácek and Lodin, 
1999) used as a disinfectant. In small doses it is common in water purification 
tablets/filters. It can be used for disinfecting spillages of blood containing many 
pathogens, including, Human immunodeficiency virus (HIV) and Hepatitis B virus 
(HBV). It has the advantage of providing a higher concentration of available chlorine and 
is less susceptible to inactivation by organic matter (McDonnell and Russell, 1999). 
However, it is corrosive to metals and at higher concentrations, irritant to skin. 
Sodium dichloroisocyanurate is stable until dissolved, rapidly effective and slightly less 
damaging to surfaces and instrument components than sodium hypochlorite. However, 
like all other chlorine-releasing agents, the use of NaDCC in hospitals is usually limited to 
environmental surfaces because of its corrosiveness.     
 
1.2.5 Disinfectant testing 
 
Disinfectant testing is important to evaluate the efficacy of the preparation for specified 
clinical applications. The activity against indicator organisms, usually common pathogens, 
remains the most important factor in selecting an appropriate disinfectant. The choice is 
best made by evaluating the activity against key organisms and comparing this activity 
with other factors such as toxicity, material compatibility, stability of the compound, user 
safety, rapidity of killing, and cost (Fraise, 1999). 
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1.2.5.1 Microbial Susceptibility 
 
Generally, different microorganisms vary in their susceptibility to disinfectants (Fig 1.1). 
Bacterial spores are the most resistant, followed by mycobacteria, and then vegetative 
form of bacteria. The lipid-enveloped viruses that comprise the HIV and HBV are readily 
inactivated by disinfectants as compared with small non-enveloped viruses e.g. poliovirus 
(Russell, 1998). 
   Prions (Creutzfeldt-Jakob disease) 
 
  Bacterial spores (Bacillus atrophaeus) 
 
  Coccidia (Cryptosporidium) 
 
  Mycobacteria (M. tuberculosis, M. terrae) 
 
  Nonlipid or small viruses (Polio, Coxsackie) 
 
  Fungi (Aspergillus, Candida) 
 
  Vegetative bacteria (Staph aureus, P. aeruginosa) 
 
  Lipid or medium sized viruses (HIV, HBV, Herpes) 
 
Figure 1.1: Decreasing order of resistance of microorganisms to disinfection and 
sterilization (Modified from Russell, 1998). 
 13
However, there are further variations within groups, with spores of Bacillus subtilis being 
more resistant than those of Clostridium difficile and Gram-negative organisms such as 
Pseudomonas aeruginosa, Providentia spp and Proteus spp being more difficult to 
inactivate (Russell, 1998).  
 
1.2.5.2  Choice of Test Organisms 
 
The Environment Protection Agency (EPA) recommends demonstration of activity 
against Salmonella choleraesuis, P. aeruginosa and S. aureus by all agents registered as 
hospital disinfectants (Centres for Disease Control, 2003). In general, microorganisms 
representing different groups and organisms generally found in the hospital environment 
are used for disinfectant testing. The following organisms have been specified and used as 
test organisms to test disinfectant efficacy for different clinical applications: 
Streptococcus mutans, Staphylococcus aureus, Candida albicans, Escherichia coli, 
Salmonella choleraesuis, Pseudomonas aeruginosa, Mycobacterium bovis, Bacillus 
subtilis spores, Hepatitis B virus, and Duck Hepatitis B virus. The European Committee 
for Standardisation (cited by van Klingeren, 1995) recommended the use of at least one 
Gram-positive and one Gram-negative organism 
 
1.2.5.3  Testing Procedures 
 
There is no specific universally accepted disinfectant testing procedure that has been 
developed. It is acceptable that available tests may be modified for specific purposes with 
regard to test strains, contact times, interfering substances (soiling, organic matter, hard 
water) and test surfaces (van Klingeren, 1995). The procedure can be designed according 
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to the type of area, in which the disinfectant will be used, what organisms is expected, 
suitable exposure time periods etc. The conditions of contact between the disinfectant and 
the organism have a significant impact on the activity of the disinfectant (Fraise, 1999). 
Many factors affect the efficacy of disinfectant, such as, hardness of water, pH of the 
solution, diluent and presence of organic material and therefore the tests have to take these 
into account. 
 
A simple procedure, called suspension test method, can be used, where rapidity of 
biocidal activity of a disinfectant can be determined in the form of percentage kill or a 
reduction factor in a specific contact time period. In this method, known quantity of 
organisms and the disinfectant are mixed in a liquid form and the solution is neutralized at 
the end of the contact time period and the solution is cultured (quantitative) for the 
surviving organisms. The percentage kill is calculated using challenged organisms and 
surviving organism count. Being an in vitro test, suspension test is useful in determining 
whether the examined preparation possesses antimicrobial activity during the specified 
contact time. It is however a poor indicator of the efficacy of the disinfectant under 
practical circumstances, especially with regard to bacteria attached to surfaces 
(Reybrouck, 1991).  
 
Another useful method is the surface or carrier test. Surface tests were developed to 
mimic the conditions of actual use of the disinfectant and hence assess the efficacy of the 
disinfectant in practice and the influence of interfering factors. In this method, the 
bacterial suspension is applied to a carrier surface and the disinfectant is then applied on 
the contaminated surface, followed by neutralisation after a specified contact time and 
sub-culturing to determine the antimicrobial activity.  
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1.2.6 Indicator organisms 
 
Microorganisms representing different groups and organisms generally found in the 
hospital environment are used for disinfectant testing. At least one gram positive and one 
gram negative organism should be included (European Committee for Standardisation). 
Depending on what situation the disinfectant is recommended to be used, test organisms 
should be selected. If the disinfectant is used in a hospital environment, types of 
organisms generally found in hospitals should be used as test organisms. Some of the 
organisms found in hospital environment are discussed. 
 
1.2.6.1 Staphylococcus aureus 
 
Staphylococcus aureus are gram positive cocci in clusters and cause both common and 
uncommon infections, such as abscesses of many organs, endocarditis, food poisoning and 
toxic shock syndrome. They are carried by healthy individuals, in their nose or on the 
skin. They are always present in the hospital environment, on hospital patients and on the 
hands of hospital staff. Methicillin-resistant S. aureus (MRSA) has become an important 
pathogen leading to hospital-acquired infections, which often leads to major morbidity 
and mortality. The principal mode of transmission for MRSA is transfer of the organism 
from a carrier or infected patient to uninfected patients by the hands or clothing of staff 
(Wang et al., 2001).  
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1.2.6.2  Psuedomonas aeruginosa 
 
Non-fermentative Gram negative rods such as, P. aeruginosa, Burkholderia cepacia and 
Stenotrophomonas maltophilia, are opportunistic pathogens responsible for nosocomial 
infections.  To better prevent nosocomial infections related to Gram negative non-
fermentative rods, the control of the aqueous hospital environment, the strict application 
of hand disinfection and the investigation of potential cross-transmission in the hospital 
setting are needed (Berthelot et al., 2005). P. aeruginosa is one of the most important 
gram-negative pathogens causing infections in ICUs. According to the US National 
Nosocomial Infections Surveillance (NNIS) system report, P. aeruginosa ranks among the 
top five pathogens associated with wound, pulmonary and urinary tract infections (NNIS, 
2004). P. aeruginosa also plays a significant role as a cause of ventilator-associated 
pneumonia (Zanetti et al., 2003). Trautmann et al., (2005) cited that approximately one 
fifth to one third of P. aeruginosa strains detected by screening cultures in the ICU were 
present on admission. The remaining fraction was apparently acquired newly in the ICU 
and cross transmissions were identified in between 8% and 50% of these newly acquired 
colonization or infections. Hospital staff was speculated to be a vector in these cases. P. 
aeruginosa has been cultured from the hands of hospital personnel and it can be 
implicated in the nosocomial transmission (Moolenar et al., 2000).  
 
1.2.6.3  Streptococcus mutans 
 
S. mutans are gram positive cocci in chains. They are viridians group of streptococci, 
commonly found in oral cavity as commensals. These bacteria are implicated in dental 
caries and are common contaminants in dental clinics. Although they are not commonly 
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used as an indicator organism for disinfectant testing, they can be used in order to 
establish the efficacy and use of the disinfectant in dental settings.  
 
1.2.6.4 Candida albicans 
 
C. albicans is unicellular, oval yeast usually endogenous in origin. Normal healthy 
individuals carry this yeast in their mouth, gastrointestinal tract and female genital tract. 
In South Africa, a study showed that 81% of HIV positive patients and 63% of HIV 
negative people carry C. albicans in their mouths (Patel et al., 2006). Colonization of this 
yeast can become a predictive value for the onset of nosocomial infection in elderly and 
immunocompromised individuals (Fanello et al., 2006). Transmission from patient to 
patient has also been suggested by Fanello et al., (2006). The major infections caused by 
this yeast are oropharyngeal and vaginal candidiasis, as well as systemic infections. The 
efficacy of many disinfectants is tested against this organism. 
 
1.2.6.5  Bacillus subtilis 
 
B. subtilis are gram positive, spore forming rod. They are saprophytic, environmental 
organism. They are non-pathogenic bacteria; however they have become popular in the 
disinfectant testing because of the spore formation. Spores are the dormant living stage of 
organisms and are difficult to eliminate. If a disinfectant is efficient in killing spores, it 
will definitely kill any vegetative form of organisms. Sodium dichloroisocyanurate, a 
chlorine based disinfectant, is an effective disinfectant against many vegetative form of 
organisms but was ineffective against bacterial spores in a hospital environment (Block C, 
2004).  
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1.2.6.6  Mycobacteria 
 
Mycobacteria are acid-fast bacilli which are commonly found in the environment. Many 
species of this genus are pathogenic to humans, animals and birds. They are very difficult 
to eliminate with common disinfectants because of the lipid content of their cell wall. 
Bactericidal disinfectants are generally considered excluding mycobacteria, unless they 
suggest mycobactericidal activity. Mycobacterium tuberculosis, the causative agent of 
tuberculosis, is generally transmitted by the airborne route. However, because of its 
resistance to drying, environmental surfaces may also act as potential vehicles of 
transmission. Improperly decontaminated flexible fibreoptic endoscopes, resuscitation and 
lung-function equipment and ventilators have also been implicated in the transmission of 
mycobacterial infection (Sattar et al., 1995). A study by Griffiths et al., (1999) showed 
that chlorine dioxide and higher concentrations of sodium dichloroisocyanurate (NaDCC) 
are rapidly mycobactericidal and glutaraldehyde was found to be a slow mycobactericide. 
The result also showed that the clinical isolate of M. avium-intracellulare was much more 
resistant than M. tuberculosis to the disinfectants.   
 
1.2.6.7  Hepatitis B virus  
 
Hepatitis B virus (HBV), a small circular, partially double-stranded DNA virus of 
approximately 3,200 base pairs, belongs to the family Hepadna viridae. The only known 
hosts for HBV are humans. It can cause acute, as well as asymptomatic disease. 
Asymptomatic disease can remain as a chronic infection, where the person becomes a 
carrier and a potential source of transmission (Mims et al., 2004). Chronic HBV infection 
can lead to liver cirrhosis and hepatocellular carcinoma (Gamen and Prince, 2004). The 
 19
transmission can occur through percutaneous or mucosal exposure to blood and other 
body fluids from infected person. Blood contains the highest HBV titres of all body fluids 
and is the most important vehicle of transmission in the healthcare setting. The most 
common marker of HBV infection is the presence of HBV surface antigen (HBsAg). 
 
Hepatitis B is a major public health problem worldwide. Approximately 350 million to 
400 million people throughout the world are chronically infected (Lee, 1997; WHO, 
2000).  Nosocomial infections caused by the Hepatitis B virus in patients during 
hospitalization and interventional procedures, as well as in health care workers, have been 
documented (CDC, 2003; Comstock et al., 2004). Infection control, including the usage of 
viricidal disinfectant is necessary in order to prevent this transmission. Transmission of 
human Hepatitis B virus (HBV) by plasma concentrates from donated blood has been 
reduced by screening and inactivation procedures. However, concern persists over 
nosocomial infections that could be acquired through inadequately disinfected equipment 
or accidental exposure of personnel to blood or other body fluids from HBV-positive 
individuals. Disinfection particularly with heptoviricidal efficacy disinfectant is an 
important measure to prevent Hepatitis B virus (HBV) transmission by instruments. 
Germicidal chemicals are important to prevent spread of HBV through re-usable devices, 
as well as in the clean-up of blood spills (Sattar et al., 2001). 
 
Study of viricidal activity of biocides is difficult because animals and tissue culture 
facilities are required. The real-time quantitative polymerase chain reaction (PCR) is 
useful for rapid screening of the killing potency of disinfectants. The ease of PCR and 
enhanced sensitivity make it more desirable (Wang et al., 2002).  Quantitative detection of 
Hepatitis B virus (HBV) in serum or plasma has become the most direct and reliable 
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method for monitoring chronic hepatitis B. HBV DNA quantification assays should 
ideally be sensitive, specific, precise, reproducible, automated, rapid and accurately 
provide HBV DNA levels in international units per millilitre (Valentine-Thon,2002). The 
COBAS® AmpliPrep/COBAS® Taqman® HBV Test provides a high-throughput sensitive 
and reliable method for quantification of HBV DNA levels in the routine molecular 
laboratory (Ronsin et al., 2006; Chevaliez et al., 2008). It is a nucleic acid amplification 
test for the quantitation of Hepatitis B virus (HBV) DNA in human plasma. The test is 
based on two major processes: specimen preparation to isolate HBV DNA and 
simultaneous PCR amplification of target DNA and detection of cleaved dual-labelled 
oligonucleotide detection probe specific to the target. Known quantity of HBV particles 
can be challenged with the test disinfectant and the resultant surviving HBV particles can 
be detected using this technique.                              
 
1.3 AIM 
 
The aim of this study was to ascertain the antimicrobial effect of slow release chlorine 
dioxide (ClO2) disinfectant (ASEPTROL®) in comparison with chlorine releasing agent 
sodium dichloroisocyanurate (PRESEPT®) using standard indicator organisms. 
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CHAPTER 2: MATERIALS AND METHODS 
   
2.1 DISINFECTANT  
Efficacy of Aseptrol® and Presept® were tested in this study.  
 
Aseptrol® (Waylor Trading and Logistics cc, South Africa) in tablet form was used to 
make the disinfectant solution. A 48ppm solution of ClO2 was made by dissolving one 
1.5g tablet of Aseptrol® in 2.5 litres of tap water according to the manufacturer’s 
instructions. The mixture was left for 20 minutes to dissolve, followed by gentle mixing 
with a glass rod. A further 2-fold dilution of the disinfectant was prepared, to obtain 
24ppm solution, by mixing 1 litre of 48ppm solution to 1 litre of tap water. 
 
Presept® (Johnson and Johnson, South Africa) solution was prepared by dissolving seven 
tablets of 2.5g each in one litre of tap water, according to the manufacturer’s instruction 
for use in blood spillage. The solution contained 10 000ppm available chlorine. 
For each experiment, disinfectant solutions were freshly prepared, just before use. 
The manufactures of these products could have taken into consideration the presence of 
chlorine in tap water. 
 
2.2 CULTURES  
 
The antimicrobial property of chlorine dioxide (Aseptrol®) and sodium 
dichloroisocyanurate (Presept®) was tested against Staphylococcus aureus (ATCC 29213), 
Pseudomonas aeruginosa (ATCC 27853), Streptococcus mutans (NCTC 1044), Candida 
albicans (ATCC 90028), Bacillus subtilis (ATCC 15244) spores, Mycobacterium 
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tuberculosis (ATCC 25177), Mycobacterium avium subsp. avium (ATCC 25291) and 
Hepatitis B virus (HBV).  S. aureus, P. aeruginosa, S. mutans, C. albicans and B. subtilis 
were obtained from Infection control laboratory, Department of Clinical Microbiology 
and Infectious Diseases, National Health Laboratory Service, Johannesburg and stored in 
semisolid agar as stock cultures. M. tuberculosis and M. avium subsp. avium were 
obtained from Mycobacteriology referral laboratory, National Health Laboratory Services, 
Braamfontein, Johannesburg and stored in aliquots at -70 oC as stock cultures. Hepatitis B 
virus was obtained from the immunology laboratory, National Health Laboratory Service, 
Braamfontein, Johannesburg and quantitated at the specialized molecular diagnostic unit 
at National Institute of Communicable Diseases, National Health Laboratory Service. 
 
2.3 PREPARATION OF INOCULA 
 
Each test organism was grown on the appropriate medium to obtain a primary culture for 
preparation of inoculum suspensions. S. aureus and P. aeruginosa were grown on 
Tryptone Soy Agar media and incubated at 37oC for 24 hours. S. mutans was grown on 
Blood agar and incubated at 37oC for 48 hours under carbon dioxide. C. albicans was 
grown on Sabouraud Dextrose Agar medium at 37oC for 48 hours. M. tuberculosis and M. 
avium subsp. avium were grown in BACTEC mycobacteria growth indicator tube (MGIT) 
liquid medium. MGIT tube contains 7ml of modified Middlebrook 7H9 Broth base and is 
one of the commonly used liquid media for the cultivation of Mycobacteria. The MGIT 
tube contains a fluorescent compound embedded in silicone on the bottom of the tube. 
The fluorescent compound is sensitive to the presence of oxygen dissolved in the broth. 
The initial concentration of dissolved oxygen quenches the emission from the compound 
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and little fluorescence can be detected. Later, actively growing and respiring micro-
organisms consume the oxygen, which allows the compound to fluoresce. 
 
BACTEC MGIT growth supplement is added to each MGIT tube to provide substances 
essential for the rapid growth of mycobacteria. Oleic acid is utilized by tubercle bacteria 
and plays an important role in the metabolism of mycobacteria. Albumin acts as a 
protective agent by binding free fatty acids which may be toxic to mycobacterium species, 
thereby enhancing their recovery. Dextrose is an energy source and catalase destroys toxic 
peroxides that may be present in the medium. Tubes are loaded into the BACTEC MGIT 
960 system and are continuously incubated at 37oC and monitored every 60 minutes for 
increasing fluorescence. An instrument positive tube, which contains approximately 105 to 
106 colony forming units per millilitres (CFU/ml), was used as an inoculum. For each 
experiment, fresh cultures were used. 
 
For S. aureus, P. aeruginosa, S. mutans and C. albicans, the resultant growth was 
harvested using a sterile wire loop and suspended in 20 ml sterile distilled water. The 
suspension was mixed by gentle shaking to obtain a homogenous organism suspension. 
The optical density of the inoculum was adjusted to 0.2 McFarland standards. 
 
B. subtilis was grown on Tryptone Soy Agar with 2 mg/l manganese sulphate (MnSO4) to 
enhance sporulation and the culture incubated at 37oC for 7 days (Perez et al., 2005). The 
Schaefer and Fulton’s method for staining spores (Jawetz et al., 1991) was used to 
confirm >90% spore production. The sporulating culture was suspended in 20ml of sterile 
distilled water and placed in a water-bath at 70oC for 20 minutes, in order to kill the 
vegetative cells.  
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The optical density of the resultant spore suspension was adjusted to 0.2 McFarland 
standards (approximately 106 test organism per milliliter) and used as an inoculum.  
 
2.4 TEST PROCEDURES FOR PERCENTAGE KILL (BACTERIA) 
This test procedure applies to S. aureus, P. aeruginosa, S. mutans, C. albicans and B. 
subtilis  
 
Standard quantitative suspension test (percentage kill) or exposure test was done. In time 
kill experiment, 2ml of 48ppm and 24ppm chlorine dioxide solution (Aseptrol®) and 
chlorine releasing solution (Presept®) were inoculated with 20μl of inoculum containing 
approximately 106 test organism per millilitre and 10μl of skim milk. Skim milk was used 
to simulate organic material. Number of organisms in the inocula was determined for each 
experiment using serial dilution test. After inoculation, every 30 seconds for 5 minutes, 
20μl of inoculated test compounds were removed, neutralized with a universal neutralizer 
(Perez et al., 2005) containing quarter strength Ringer’s solution, 0.5% Tween 80 and 
0.5% sodium thiosulphate, diluted and then spread onto appropriate medium to achieve 
the number of surviving organisms. Culture plates were incubated at 37oC for 24 or 48 
hours depending on the type of organism. The colony count for each plate was determined 
and percentage kill was calculated using the inoculum count. The formula is given below: 
 
Challenged org. (Inoculum count) – (surviving org) 
                                                                                        X 100 = percentage (%) kill 
Challenged org. (Inoculum count) 
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Time taken to kill the challenged organisms was recorded against percentage kill. For 
each test organism, experiment was repeated 5 times using 48ppm, 24ppm chlorine 
dioxide solution (Aseptrol®) and sodium dichloroisocyanurate chlorine solution 
(Presept®).  
 
2.5 TEST PROCEDURE FOR PERCENTAGE KILL (MYCOBACTERIA) 
This test procedure applies to M. tuberculosis and M. avium subsp. avium. 
 
Quantitative suspension test described by Hernández et al., (2003) was used in this study.  
Cultures were grown in the BACTEC mycobacteria growth indicator tube (MGIT). Viable 
bacterial count was obtained using serial dilution technique. 20µl of this prepared 
suspension was added to 2ml of disinfectant, containing 10µl of skim milk. After 
inoculation, every 30 seconds for 5 minutes, 20μl of inoculated test compound was 
removed, neutralized with a universal neutralizer, and spread onto middlebrook 7H10 agar 
plate. Culture plates were incubated at 37oC for 4 -6 weeks. The colony count for each 
plate was determined and percentage kill calculated using the inoculum count. Percentage 
kill was recorded for each contact time period.  
 
Each experiment was repeated 5 times using 48ppm, 24ppm chlorine dioxide solution 
(Aseptrol®) and sodium dichloroisocyanurate chlorine solution (Presept®).  
 
2.6 TEST PROCEDURE FOR PERCENTAGE KILL (Hepatitis B Virus) 
 
COBAS® Ampliprep/COBAS® Taqman® HBV Test was performed to test the efficacy of 
test disinfectant against Hepatitis B virus. It is a nucleic acid amplification test for the 
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quantitation of Hepatitis B virus (HBV) DNA in human plasma. The test is based on two 
major processes: specimen preparation to isolate HBV DNA and simultaneous PCR 
amplification of target DNA and detection of cleaved dual-labelled oligonucleotides 
detection probe specific to the target. The test combines the COBAS® Ampliprep 
instrument, which performs fully automated extraction of HBV DNA and the COBAS® 
Taqman® 48 Analyzer, which performs fully automated real-time PCR amplification and 
detection, followed by interpretation of HBV DNA levels by means of Amplilink® 
software. 
 
The Quantitation of HBV DNA was performed using HBV Quantitation standard (QS). 
The QS compensates for the effects of inhibition and controls the preparation and 
amplification process. It was added through all the steps of specimen preparation, 
amplification and detection of dual labelled oligonucleotides detection probes. The Master 
Mix reagent contained primer pairs and probes specific for both HBV DNA and HBV QS 
DNA. The HBV DNA concentration in the test specimen was calculated by the COBAS® 
Taqman® analyzer by comparing the HBV QS signal for each control and specimen 
(Roche Molecular Systems). 
 
2.6.1 Target selection 
 
Selection of the target DNA sequence for HBV depends on identification of regions 
within the HBV genome that show maximum sequence conservation among the various 
HBV genotypes. Generic silica-based specimen preparation was used to capture the HBV 
DNA and HBV QS DNA and defined oligonucleotides are used as primers in 
amplification of the HBV DNA and HBV QS DNA. A target-specific and a QS-specific 
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dual-labelled oligonucleotides probe permitted independent identification of HBV 
amplicon. The appropriate selection of the primers and the dual-labelled oligonucleotides 
probe was critical to the ability of the test to amplify and detect the HBV genotypes. The 
COBAS® Taqman® HBV Test used three amplification primers for PCR. 
 
2.6.2 Specimen preparation 
 
 The COBAS® Ampliprep/COBAS® Taqman® HBV Test utilized automated specimen 
preparation on the COBAS® Ampliprep instrument by a generic silica-based capture 
technique. The procedure processes 850μl of plasma. The HBV virus particles were lysed 
by incubation at elevated temperature with a protease and chaotropic lysis/binding buffer 
that released nucleic acids and protected the released HBV DNA from DNases in plasma. 
Protease and a known number of HBV QS DNA molecules were introduced into each 
specimen along with the lysis reagent and magnetic glass particles. The mixture was 
incubated and the HBV DNA and HBV QS DNA are bound to the surface of the glass 
particles. Unbound substances were removed by washing the magnetic glass particles. The 
processed specimen, containing the magnetic glass particles, as well as released HBV 
DNA and HBV QS DNA, was added to the amplification mixture and transferred to the 
COBAS® Taqman® 48 Analyzer.  
 
2.6.3 PCR Amplification 
 
The PCR amplification reaction was performed with the thermostable recombinant 
enzyme Thermus specie DNA Polymerase (Z05). In the presence of manganese (Mn²+) 
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and under the appropriate buffer condition, Z05 has DNA activity. This allowed PCR 
amplification to occur together with real-time detection of the amplicon. 
 
Processed specimens were added to the amplification tubes (K-tubes) in which PCR 
amplification occurs. The thermal Cycler in the COBAS®Taqman® Analyser heats the 
reaction mixture to denature the double-stranded DNA and expose the specific primer 
target sequences on the HBV circular DNA genome and the HBV QS DNA. As the 
mixture cools, the primers anneal to the target DNA. In the presence of Mn²+ and excess 
deoxynucleotide triphosphates (dNTPs), including deoxyadenosine, deoxyguanosine, 
deoxycytidine and deoxyuridine triphosphates, Z05 polymerase extends the annealed 
primers along the target template to produce a double-stranded DNA molecule, termed an 
amplicon. The COBAS®Taqman® Analyser automatically repeats this process for a 
designated number of cycles, with each cycle intended to double the amount of amplicon 
DNA. 
 
2.6.4 Detection of PCR products 
 
The use of dual-labelled fluorescent probes allows for real-time detection of PCR product 
accumulation by monitoring of the emission intensity of fluorescent reporter dyes released 
during the amplification process. The probes consist of HBV and HBV QS-specific 
oligonucleotides probes with a reporter dye and a quencher. When these probes are intact, 
the fluorescence of the reporter dye is suppressed by the proximity of the quencher due to 
Förster-type energy transfer effects.  
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Once the reporter and quencher dyes are released and separated, quenching no longer 
occurs and the fluorescent activity of the reporter dye is increased. The amplification of 
HBV DNA and HBV QS DNA are measured independently at different wavelengths. 
 
These fluorescent readings are sent by the instrument to the AMPLILINK® software and 
stored in a database. The COBAS® Ampliprep/ COBAS® Taqman® HBV Test is 
standardized against WHO international standard for Hepatitis B virus DNA for Nucleic 
Acid Technology (NAT) assays testing (NIBSC 97/746) and titer results are reported in 
international units (IU/Ml). 
 
2.6.5 HBV DNA Quantification 
 
The test was performed using COBAS® Ampliprep/COBAS® Taqman® HBV test kit 
(described as above), according to the manufacturer’s instructions. HBV CS1 (HBV 
magnetic glass particles reagent cassette) was placed onto a reagent rack and put into 
position A of the COBAS® Ampliprep instrument. HBV CS2 (HBV lysis reagent 
cassette), HBV CS3 (HBV multi-reagent cassette) and HBV CS4 (HBV test-specific 
reagent cassette) were placed into a separate reagent rack and loaded into rack position B, 
C, D or E. Sample processing units (SPUs) were placed in the racks and loaded onto 
appropriate rack position. Full K-tube and K-tip racks were also loaded in their positions. 
One millilitre of controls (negative, low positive and high positive) and 960µl of HBV-
negative human EDTA-plasma were manually transferred into barcode-labelled sample 
input tubes (S-tubes). 20µl of universal neutralizer was added to each S-tube containing 
HBV-negative human EDTA-plasma. 20µl of positive HBV, with known viral load (1.0 X 
105 iu/ml), was added to 2ml of disinfectant. Every 30 seconds for 5 minutes, 20µl of the 
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mixture was removed and added to the S-tubes and then placed into sample racks and 
loaded in the COBAS® Ampliprep instrument. Using the COBAS® Ampliprep instrument 
connected to the COBAS® Taqman® via docking station, transfer of extracted material for 
amplification and detection occurred automatically. After completion of the COBAS® 
Taqman® analyzer, the result reports were printed. The COBAS® Taqman® analyzer 
automatically determined the HBV DNA concentration for the specimens and controls 
and expressed them in IU/ml. 
 
Skim milk was not added in these tests because plasma represented organic material.  
The test was performed 5 times using 48ppm and 24ppm Aseptrol® solution and 
Presept® solutions. 
 
2.7 SHELF-LIFE STUDY PROCEDURE 
 
According to manufacturer’s recommendation, concentrations of Aseptrol® (48ppm) and 
Presept® (10 000ppm) were prepared. Time-kill study using above organisms were 
performed on the same day at contact time periods of 30 and 60 seconds and thereafter 
every fifth day. After 20 days, the test was performed everyday. Same experiment was 
performed until the prepared disinfectant solutions became ineffective. The last effective 
day for each organism was recorded. Only the qualitative analysis was done.  
This test was not performed for B. subtilis spores and Hepatitis B virus. The test was 
performed once for the rest of the test organisms. 
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2.8 STATISTICAL ANALYSIS 
 
Percentage kill study was performed 5 times for each test organism and each test 
concentration of the two disinfectants. Descriptive statistical analysis was performed. 
Mean and standard deviations were recorded. 
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CHAPTER 3: RESULTS 
 
 
3.1   EFFECT OF ASEPTROL® AND PRESEPT® ON TEST ORGANISMS 
 
The results are presented in table form (Tables 3.1 – 3.9). Each table contains results of 
one test microorganism, two concentrations of Aseptrol® and one concentration of 
Presept®. Each concentration was tested 5 times, therefore 5 results are depicted. The 
inoculum count for each test is given and the percentage kill is calculated and described. 
Mean of percentage kill for each concentration is also calculated. 
 
3.1.1 Effect of test disinfectants on S. aureus 
 
Aseptrol® at concentrations 48ppm and 24ppm and Presept® at 10 000ppm killed 
approximately 106 CFU of S. aureus within 30 seconds (Table 3.1). The results are 
reproducible because the test was repeated 5 times and the results did not differ.  
 
3.1.2 Effect of test disinfectants on P. aeruginosa 
 
Aseptrol® at concentrations 48ppm and 24ppm and Presept® at 10 000ppm killed 
approximately 106 CFU of P. aeruginosa within 30 seconds (Table 3.2). The results are 
reproducible because the test was repeated 5 times and the results did not differ.  
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3.1.3 Effect of test disinfectants on S. mutans 
 
Aseptrol® at concentrations 48ppm and 24ppm and Presept® at 10 000ppm killed 
approximately 106 CFU of S. mutans within 30 seconds (Table 3.3). The results are 
reproducible because the test was repeated 5 times and the results did not differ.  
 
3.1.4 Effect of test disinfectants on C. albicans 
 
Aseptrol® at concentrations 48ppm and 24ppm and Presept® at 10 000ppm killed 
approximately 104 CFU of C. albicans within 30 seconds (Table 3.4). The results are 
reproducible because the test was repeated 5 times and the results did not differ.  
 
3.1.5 Effect of test disinfectants on B. subtilis spores 
 
Aseptrol® at concentrations 48ppm and 24ppm and Presept® at 10 000ppm killed 
approximately 105 to 106 CFU of B. subtilis spores within 2 and 2.5 minutes (Table 3.5). 
In this table, after the exposure to disinfectants, number of surviving organisms is also 
given because the percentage kill was not 99.99 in every test. Aseptrol® performed 
slightly better than Presept®. The survival of B. subtilis spores varied in each test, 
therefore mean and standard deviations were calculated. The results also showed that at 
ineffective contact time periods, five test results were different and therefore standard 
deviations are high. However, as the contact time period increased, the test concentration 
became effective and consistent results were obtained showing low standard deviations. 
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3.1.6 Effect of test disinfectants on M. tuberculosis and M. avium subsp. avium 
 
Aseptrol® at concentrations 48ppm and 24ppm and Presept® at 10 000ppm killed 
approximately 105 CFU of M. tuberculosis and M. avium subsp. avium within 30 seconds 
(Tables 3.6 and 3.7). The results are reproducible because the test was repeated 5 times 
and the results did not differ.  
 
3.1.7 Effect of test disinfectants on Hepatitis B virus 
 
Aseptrol® at concentrations 48ppm and 24ppm and Presept® at 10 000ppm killed 
approximately 105 particles of Hepatitis B virus within 30 seconds (Table 3.8). The results 
are reproducible because the test was repeated 5 times and the results did not differ.  
 
The Summary of above results is shown in Table 3.9, where it is clear that both 
disinfectants are bactericidal, mycobactericidal, fungicidal and viricidal at 30 seconds 
exposure. They are sporicidal at 2 – 2.5 minutes contact time period. 
 
3.2 ANTIMICROBIAL SHELF-LIFE OF ASEPTROL® AND PRESEPT® 
 
This test was not performed for Hepatitis B virus and B. subtilis spores. Although the 
manufacturers recommend the disinfectant solutions should be prepared daily, the results 
showed that if Aseptrol® solution is prepared and stored in a screw cap bottles, it retains 
bactericidal effect for at least 27 days with contact time period of 30 seconds (Table 3.10). 
On the other hand, Presept® was found to be effective even until 37 days. The tests were 
not performed after 37 days (Table 3.10).     
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 Table 3.1   The effect of Aseptrol® and Presept® on S. aureus at various contact time period.  
 
Disinfectant 
 
Tests 
 
No. of 
challenged 
organisms 
Cfu/ml 
 
Percentage kill (%) and contact time period (minutes) 
 
½ min 
 
1 min 
 
1½ 
min 
 
2 min 
 
2½ 
min 
 
3 min 
 
3½ 
min 
 
4 min 
 
4½ 
min 
 
5 min 
 
Aseptrol® 
48 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
1.8 X 106 
1.8 X 106 
4.7 X 106 
4.7 X 106 
4.7 X 106 
 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
Aseptrol® 
24 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
1.8 X 106 
1.8 X 106 
4.7 X 106 
4.7 X 106 
4.7 X 106 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
Presept® 
10 000 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
1.8 X 106 
1.8 X 106 
4.7 X 106 
4.7 X 106 
4.7 X 106 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
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Table 3.2   The effect of Aseptrol® and Presept® on P. aeruginosa at various contact time period.  
  
Disinfectant 
 
Tests 
 
No. of 
challenged 
organisms 
Cfu/ml 
 
Percentage kill (%) and contact time period (minutes) 
 
½ min 
 
1 min 
 
1½ 
min 
 
2 min 
 
2½ 
min 
 
3 min 
 
3½ 
min 
 
4 min 
 
4½ 
min 
 
5 min 
 
Aseptrol® 
48 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
1.1 X 106 
1.1 X 106 
1.1 X 106 
1.1 X 106 
1.1 X 106 
 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
Aseptrol® 
24 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
1.1 X 106 
1.1 X 106 
1.1 X 106 
1.1 X 106 
1.1 X 106 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
Presept® 
10 000 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
1.1 X 106 
1.1 X 106 
1.1 X 106 
1.1 X 106 
1.1 X 106 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
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Table 3.3   The effect of Aseptrol® and Presept® on S. mutans at various contact time period.   
 
Disinfectant 
 
Tests 
 
No. of 
challenged 
organisms 
Cfu/ml 
 
Percentage kill (%) and contact time period (minutes) 
 
½ min 
 
1 min 
 
1½ 
min 
 
2 min 
 
2½ 
min 
 
3 min 
 
3½ 
min 
 
4 min 
 
4½ 
min 
 
5 min 
 
Aseptrol® 
48 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
1.4X 106 
1.4X 106 
1.4X 106 
1.4X 106 
1.4X 106 
 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
Aseptrol® 
24 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
1.4X 106 
1.4X 106 
1.4X 106 
1.4X 106 
1.4X 106 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
Presept® 
10 000 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
1.4X 106 
1.4X 106 
1.4X 106 
1.4X 106 
1.4X 106 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
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Table 3.4   The effect of Aseptrol® and Presept® on C. albicans at various contact time period. 
 
Disinfectant 
 
Tests 
 
No. of 
challenged 
organisms 
Cfu/ml 
 
Percentage kill (%) and contact time period (minutes) 
 
½ min 
 
1 min 
 
1½ 
min 
 
2 min 
 
2½ 
min 
 
3 min 
 
3½ 
min 
 
4 min 
 
4½ 
min 
 
5 min 
 
Aseptrol® 
48 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
6.0 X 104 
6.0 X 104 
6.0 X 104 
6.0 X 104 
6.0 X 104 
 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
Aseptrol® 
24 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
6.0 X 104 
6.0 X 104 
6.0 X 104 
6.0 X 104 
6.0 X 104 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
Presept® 
10 000 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
6.0 X 104 
6.0 X 104 
6.0 X 104 
6.0 X 104 
6.0 X 104 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
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Table 3.5   The effect of Aseptrol® and Presept® on B. subtilis spores at various contact time period.  
 
Disinfect-
ant 
 
Tests 
 
No. of 
challenged 
organisms 
Cfu/ml 
 
½ min 
 
1 min 
 
1½ min 
 
2 min 
 
2½ min 
No. 
surviving 
org 
cfu/ml 
% kill No. 
surviving 
org cfu/ml
% kill No. 
surviving 
org 
cfu/ml 
% kill No. 
surviving 
org 
cfu/ml 
% kill No. 
surviving 
org 
cfu/ml 
% kill 
Aseptrol® 
48 ppm 
 
 
1 
2 
3 
4 
5 
Mean
±SD 
 
3.4 X 106 
3.5 X 105 
3.5 X 105 
3.5 X 105 
3.5 X 105 
 
 
 
2.6 X 106 
1.8 X 105 
1.3 X 105 
1.1 X 105 
1.2 X 105 
 
 
 
23.53 
48.57 
62.86 
68.57 
65.71 
53.85± 
18.61 
 
3.0 X 104 
5.0 X 103 
3.5 X 104 
3.0 X 104 
5.0 X 103 
 
 
 
99.12 
98.57 
90 
91.43 
98.57 
95.54± 
4.44 
 
4.8 X 103 
5.0 X 103 
5.0 X 103 
5.0 X 103 
5.0 X 103 
 
99.86 
98.57 
98.57 
98.57 
98.57 
98.83± 
0.58 
 
0 
0 
0 
0 
0 
 
99.99 
99.99 
99.99 
99.99 
99.99 
99.99± 
0 
 
0 
0 
0 
0 
0 
 
99.99 
99.99 
99.99 
99.99 
99.99 
99.99± 
0 
Aseptrol® 
24 ppm 
 
 
1 
2 
3 
4 
5 
Mean
±SD 
 
3.4 X 106 
3.5 X 105 
3.5 X 105 
3.5 X 105 
3.5 X 105 
 
 
1.4 X 106 
1.4 X 105 
1.0 X 105 
1.5 X 105 
2.0 X 105 
 
58.8 
60 
71.43 
57.14 
42.86 
58.05± 
10.18 
 
4.9 X 104 
1.3 X 105 
1.0 X 104 
5.0 X 103 
5.0 X 103 
 
 
98.56 
62.86 
97.14 
98.57 
98.57 
91.14± 
15.82 
 
4.9 X 104 
5.0 X 103 
5.0 X 103 
5.0 X 103 
5.0 X 103 
 
 
98.56 
98.57 
98.57 
98.57 
98.57 
98.57± 
0 
 
0 
0 
0 
0 
0 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
99.99± 
0 
 
0 
0 
0 
0 
0 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
99.99± 
0 
Presept® 
10 000 
ppm 
 
 
1 
2 
3 
4 
5 
Mean
±SD 
 
3.4 X 106 
3.5 X 105 
3.5 X 105 
3.5 X 105 
3.5 X 105 
 
2.4 X 105 
1.0 X 105 
2.7 X 105 
1.6 X 105 
1.0 X 105 
 
92.94 
71.43 
22.86 
54.29 
71.43 
62.59± 
26.10 
 
1.0 X 104 
4.9 X 104 
1.2 X 105 
9.0 X 104 
2.5 X 104 
 
99.70 
86 
65.71 
74.29 
92.86 
83.71± 
13.76 
 
4.8 X 103 
5.0 X 103 
5.0 X 103 
5.0 X 103 
5.0 X 103 
 
 
99.86 
98.57 
98.57 
98.57 
98.57 
98.83± 
0.58 
 
5.0 X 103 
5.0 X 103 
5.0 X 103 
5.0 X 103 
5.0 X 103 
 
 
 
99.85 
98.57 
98.57 
98.57 
98.57 
98.83± 
0.57 
 
0 
0 
0 
0 
0 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
99.99± 
0 
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Table 3.6      The effect of Aseptrol® and Presept® on M. tuberculosis at various contact time period. 
 
Disinfectant 
 
Tests 
 
No. of 
challenged 
organisms 
Cfu/ml 
 
Percentage kill (%) and contact time period (minutes) 
 
½ min 
 
1 min 
 
1½ 
min 
 
2 min 
 
2½ 
min 
 
3 min 
 
3½ 
min 
 
4 min 
 
4½ 
min 
 
5 min 
 
Aseptrol® 
48 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
5.0 X 105 
5.0 X 105 
5.0 X 105 
5.0 X 105 
5.0 X 105 
 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
Aseptrol® 
24 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
5.0 X 105 
5.0 X 105 
5.0 X 105 
5.0 X 105 
5.0 X 105 
 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
Presept® 
10 000 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
5.0 X 105 
5.0 X 105 
5.0 X 105 
5.0 X 105 
5.0 X 105 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
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Table 3.7       The effect of Aseptrol® and Presept® on M. avium subsp. avium at various contact time period.   
 
Disinfectant 
 
Tests 
 
No. of 
challenged 
organisms 
Cfu/ml 
 
Percentage kill (%) and contact time period (minutes) 
 
½ min 
 
1 min 
 
1½ 
min 
 
2 min 
 
2½ 
min 
 
3 min 
 
3½ 
min 
 
4 min 
 
4½ 
min 
 
5 min 
 
Aseptrol® 
48 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
0.4 X 105 
0.4 X 105 
0.4 X 105 
0.4 X 105 
0.4 X 105 
 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
Aseptrol 
24 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
0.4 X 105 
0.4 X 105 
0.4 X 105 
0.4 X 105 
0.4 X 105 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
Presept 
10 000 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
0.4 X 105 
0.4 X 105 
0.4 X 105 
0.4 X 105 
0.4 X 105 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
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Table 3.8 The effect of Aseptrol® and Presept® on Hepatitis B virus at various contact time period.   
 
Disinfectant 
 
Tests 
 
No. of 
challenged 
 
 
Percentage kill (%) and contact time period (minutes) 
 
½ min 
 
1 min 
 
1½ 
min 
 
2 min 
 
2½ 
min 
 
3 min 
 
3½ 
min 
 
4 min 
 
4½ 
min 
 
5 min 
 
Aseptrol® 
48 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
1.0 X 105 
1.0 X 105 
1.0 X 105 
1.0 X 105 
1.0 X 105 
 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
Aseptrol® 
24 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
1.0 X 105 
1.0 X 105 
1.0 X 105 
1.0 X 105 
1.0 X 105 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
Presept® 
10 000 ppm 
 
 
1 
2 
3 
4 
5 
 
Mean 
 
1.0 X 105 
1.0 X 105 
1.0 X 105 
1.0 X 105 
1.0 X 105 
 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
 
99.99 
99.99 
99.99 
99.99 
99.99 
 
99.99 
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Table 3.9 Summary of Percentage kill of the test organisms by chlorine dioxide (Aseptrol®) and chlorine (Presept®) releasing disinfectants 
 
 
Disinfectant
 
Test org. 
Mean No. of 
challenged org.  
cfu/ml or iu/ml 
Percentage kill (%) and contact time period Mean ± SD, n=5
 
½ min 
 
1 min 
 
1½ min 
 
2 min 
 
2½ min 
Aseptrol®     
48 ppm 
available 
chlorine 
 
S. aureus 
P. aeruginosa 
S. mutans 
C. albicans 
M. tuberculosis 
M. avium complex 
Hepatitis B virus 
4.7 X 106
1.1 X 106 
1.4 X 106 
6.0 X 104 
5.0 X 105 
4.0 X 104 
1.0 X 105 
 
 
 
99.99±0.00 
 
 
 
99.99±0.00 
 
 
 
99.99±0.00 
 
 
 
 
 
99.99±0.00 
 
 
 
99.99±0.00 
 
B. subtilis spores 6.8 X 106 61.43±7.69 95.54±4.44 98.83±0.58
Aseptrol®     
24 ppm 
available 
chlorine 
 
S. aureus 
P. aeruginosa 
S. mutans 
C. albicans 
M. tuberculosis 
M. avium complex 
Hepatitis B virus 
4.7 X 106
1.1 X 106 
1.4 X 106 
6.0 X 104 
5.0 X 105 
4.0 X 104 
1.0 X 105
 
 
 
99.99±0.00 
 
 
 
99.99±0.00 
 
 
 
99.99±0.00 
 
 
 
 
 
99.99±0.00 
 
 
 
99.99±0.00 
 
B. subtilis spores 6.8 X 106 58.05±10.18 91.43±15.18 98.57±0.00
   Presept® 
10 000 ppm 
available 
chlorine 
 
S. aureus 
P. aeruginosa 
S. mutans 
C. albicans 
M. tuberculosis 
M. avium complex 
Hepatitis B virus 
4.7 X 106
1.1 X 106 
1.4 X 106 
6.0 X 104 
5.0 X 105 
4.0 X 104 
1.0 X 105
 
 
 
99.99±0.00 
 
 
 
99.99±0.00 
 
 
 
99.99±0.00 
 
 
 
 
 
99.99±0.00 
 
 
 
99.99±0.00 
 
B. subtilis spores 6.8 X 106 63.19±25.49 83.18±13.02 98.83±0.58 98.57±0.00
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Table 3.10   Antimicrobial shelf-life of Aseptrol® and Presept® 
 
 
 
Organisms 
 
 
Disinfectant 
Effectiveness (days) 
Time taken to kill 
30 seconds 60 seconds 
S.  aureus 
 
Aseptrol® 27 27 
Presept® >37 >37 
P. 
aeruginosa 
Aseptrol® 35 >37 
Presept® >37 >37 
S. mutans 
 
Aseptrol® 35 >37 
Presept® >37 >37 
C. albicans 
 
Aseptrol® 30 >37 
Presept® >37 >37 
M. 
tuberculosis 
Aseptrol® >28 >28 
Presept® >28 >28 
M. avium 
subsp. avium 
Aseptrol® >28 >28 
Presept® >28 >28 
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CHAPTER 4: DISCUSSION 
 
 
Chlorinated disinfectants have been used for a long time in healthcare settings and the 
antimicrobial activity of chlorine is attributed to undissolved hypochlorous acid (HOCl). 
However, these compounds are relatively unstable and the activity is dependent on pH 
(Dychdala GR, 2001). Demand-release chlorine dioxide compounds were introduced 
because they retain chorine longer and so exert a more prolonged bactericidal effect and 
they are stable. One such formula, Presept®, containing sodium dichloroisocyanurate, was 
studied here. Some formulas are prepared with similar compound but corrosion inhibitors 
are added, which become activated at the time of solution preparation. In this study, such 
formula was Aseptrol® which releases chlorine dioxide. Low- level disinfectants are 
expected to be effective against most vegetative bacteria, some viruses and fungi but 
cannot be relied on to kill resistant micro-organisms e.g. M. tuberculosis or bacterial 
spores. Intermediate-level disinfectants kill M. tuberculosis, vegetative bacteria, most 
viruses and fungi but not necessarily bacterial spores. High-level disinfectants destroy all 
micro-organisms with the exception of high numbers of bacterial spores. Although many 
studies have shown chlorinated compounds to have good microbicidal activity, including 
activity against HBV and mycobacteria (Bond et al., 1983; Griffiths et al., 1999; 
Silverman et al., 1999; Weber et al., 1999), it has been considered intermediate level 
disinfectant purely because of the low sporicidal activity. In this study, the results showed 
that both disinfectants had bactericidal activity at 30 seconds contact time period. 
 
S. aureus, P. aeruginosa, S. mutans and C. albicans are easily eliminated by chlorinated 
compounds and it was shown in this study but challenge is the mycobacteria, Hepatitis B 
and bacterial spores. This study showed that Aseptrol® and Presept® had not only 
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bactericidal but mycobactericidal, viricidal and sporicidal activity at half to 2 minutes 
contact time period. This suggests that it can be used as an intermediate level disinfectant, 
as well as a high-level disinfectant. Our results are comparable to the results obtained by 
Isomoto et al., (2006), where they found 30ppm chlorine dioxide to be mycobactericidal in 
60 seconds and sporicidal in 1 to 5 minutes.  
 
4.1    USE OF DISINFECTANTS AND STERILANTS IN SEMICRITICAL  AREAS 
 
The United States Environmental Protection Agency (EPA) regulates surface disinfectants 
and the tuberculocidal claim is an EPA benchmark for measuring germicidal potency. 
Among microorganisms, such as the vegetative bacteria, viruses and fungi, mycobacteria 
(including M. tuberculosis), have the highest intrinsic level of resistance to disinfectants. 
Therefore, any germicide with a tuberculocidal claim on the label must be capable of 
inactivating a broad spectrum of pathogens, including Hepatitis B virus, Hepatitis C virus 
and Human immune-deficiency virus (Cleveland et al., 2009). Results in this study have 
also shown that test disinfectants are mycobactericidal and proved to have broad spectrum 
activity. 
 
Objects that enter sterile tissue or the vascular system such as surgical instruments, 
cardiac, urinary catheters etc must be sterile because microbial contamination could 
transmit diseases. Usually most items are purchased sterile or they are sterilized with 
steam or heat-sensitive ones are sterilised with ethylene oxide or hydrogen hydroxide gas 
plasma.  However, if these methods are unsuitable, then chemical sterilants are required. 
These sterilants are high level disinfectants. Some chemicals such as glutaraldehyde, 
hydrogen peroxide and peracetic acid based formulas are used as sterilants. Generally 
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chlorinated compounds are not considered as sterilants due to their ineffectiveness and 
corrosive property. Bronchoscopes can transmit M. tuberculosis between patients (Larson 
et al., 2003). Inadequate cleaning and disinfection of the instruments and accessories are 
likely contributing factors (Ayliffe, 2000; Lisgaris, 2003; Nelson, 2003). The only 
practical means of disinfecting heat labile, flexible bronchoscopes between patients is 
immersion in a suitably efficacious and non-damaging disinfectant (Babb, 1993; Ayliffe, 
2000). In this study, we studied two chlorine based disinfectants and the results showed 
that both disinfectants can be used as sterilants, regarded that the contact time period is 
more than two minutes. Aseptrol® is non-corrosive, therefore can be used for metal 
instruments as well. After disinfection of endoscopes using chlorine dioxide, Isomoto et 
al., (2006) observed no functional or cosmetic damage in the instruments or accessories. 
They suggested that the use of chlorine dioxide, together with thorough pre-cleaning, can 
offer effective, faster and less problematic endoscope disinfection. 
 
Disinfection is an important measure to prevent transmission of many infections by 
instruments. The CDC recommendation for high level disinfection of HBV-, HCV- , HIV- 
or mycobacteria-contaminated devices is appropriate and many studies have demonstrated 
the effectiveness of high-level disinfectants to inactive these and other pathogens that 
might contaminate semicritical devices (Bond et al., 1983; Hanson et al., 1990; Rutala et 
al., 1991; Sattar and springthorpe, 1991; Chanzy et al, 1999; Payan et al., 2004).   
 
Haemodialysis systems include haemodialysis machines, water supply, water-treatment 
systems, and distribution systems. During haemodialysis, patients have acquired blood 
borne viruses and pathogenic bacteria (Alter et al., 2004) and therefore, cleaning and 
disinfection of this unit is important. EPA and Food and Drug Administration (FDA) 
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regulate disinfectants used to reprocess hemodialyzer, haemodialysis machine and water 
treatment systems. Hemodialyzer, haemodialysis systems are usually disinfected by 
chlorine-based disinfectants (500-600 ppm free chlorine). Aseptrol® and Presept® which 
were tested here can easily be used in this situation, particularly Aseptrol®, at much lower 
concentrations. Aseptrol® can be used for noncritical surfaces such as dialysis bed or 
chair, countertops and external surfaces of dialysis machines because it is noncorrosive to 
metals. In this study, surface/carrier disinfection testing was not done because it had been 
established by Rweyendela et al., (2009). In their study, impression materials were used 
instead of blocks and both disinfectants had good antimicrobial activity. 
 
4.2 ROLE OF ORGANIC MATERIAL 
 
All disinfectants are less effective in the presence of organic material (blood, saliva, body 
fluids), meaning, “you can't disinfect dirt”. Organic matter interferes with the action of 
disinfectants by: coating the pathogen and preventing contact with the disinfectant; 
forming chemical bonds with the disinfectants, thereby making it inactive against 
organisms; or reacting chemically with and neutralizing the disinfectant. Cleaning before 
the application of the disinfectant is essential. Here, tests were performed in the presence 
of organic material (skim milk and plasma), which suggests organic material did not 
compromise the efficacy of the disinfectants. However, some studies have shown that 
organic material can compromise the efficacy. Therefore Isomoto et al., (2006) has 
suggested that the use of chlorine dioxide together with precleaning in endoscope 
disinfection is still advantageous over glutaraldehyde due to its fast, effective and less 
problematic disinfection.  
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4.3 VIRICIDAL ACTIVITY 
 
In this study, both disinfectants showed viricidal activity, therefore they can be used on 
surfaces that are contaminated with blood and blood spillages. For testing of HBV, HBV-
negative human EDTA-plasma was used to make up the required volume and this organic 
material did not affect the microbicidal properties of chlorine and chlorine dioxide. This is 
contrary to the finding of Isomoto et al., (2006), who showed that organic material can 
compromise the efficacy of chlorinated compounds.   
 
4.4 MYCOBACTERICIDAL ACTIVITY 
 
Tuberculosis (TB) generally spreads through air but improperly decontaminated medical 
devices have also been implicated in its transmission.  Environmental surfaces act as 
vehicles for mycobacteria. M. tuberculosis can survive for several days on inanimate 
surfaces (cited by Sattar et al., 1995). Non-tuberculous mycobacteria (NTM) are usually 
saprophytes but can be opportunistic and at times deadly pathogens. In the 
immunocompromised individuals, infections due to NTM have been observed to be an 
important cause of morbidity and mortality in the western countries (Wallace et al., 1990). 
Appropriate use of cleaners and disinfectants can minimize the incidence of health-care-
associated infections and pseudo-outbreaks (Sehulster et al., 2003). Nosocomial infections 
and outbreaks caused by inadequate disinfection/sterilization of medical devices are well 
described (Larson et al., 2003). Pulmonary disease, lymphadenitis, skin, soft tissue, 
skeletal infections, catheter-related blood-stream infections in immunocompromised hosts 
and disseminated disease in persons with acquired immune-deficiency syndrome (AIDS) 
are clinical syndromes attributed to mycobacteria. M. avium complex infection results 
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from diverse and likely undetectable environmental and nosocomial exposures (Von Reyn 
et al., 2002). A study conducted by Griffiths et al., (1999) showed that chlorine releasing 
agents are effective against mycobacteria and blood borne viruses. In suspension tests, 
chlorine at 1100ppm was as effective as 10 000ppm sodium dichloroisocyanurate in 
achieving a Log 10 reduction >5 in M. tuberculosis and M. avium-intracellulare, tested 
under 1 minute (Griffiths et al., 1999). They also found that clinical isolates of M. avium-
intracellulare was more resistant than Mycobacterium tuberculosis to Chlorine dioxide 
and sodium dichloroisocyanurate. However this study demonstrated 99.99% kill of M. 
tuberculosis and M. avium subp. avium by both disinfectants within 30 seconds. These 
results can categorise Aseptrol® and Presept® to be intermediate to high level 
disinfectants. Mycobactericidal disinfectants are also required for laboratory and 
respiratory equipment, the fixation of tissue and for removing culture and body fluid 
spills. These disinfectants could easily be used in those situations. 
  
4.5 USE OF DISINFECTANTS IN DENTAL SETTINGS 
 
Potential for transmission of infectious agents in dentistry have been stressed (Lewis et al., 
1992, Lewis and Boe, 1992). In dental settings surfaces frequently touched by 
contaminated gloves, instruments, light handles become contaminated by saliva and blood 
and related organisms. Dental caries is one of the most prevalent diseases in humans; it 
causes irreversible damage to the grinding machinery involved in the intake of food and 
causes great distress. The change in the homeostasis of the oral cavity, with an overgrowth 
of S. mutans is recognized as the primary cause of the disease. In surgeries, due to the 
dental procedures, tremendous amount of blood contaminated salivary aerosols are 
created. These aerosols can be contaminated with caries causing S. mutans, oral 
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candidiasis causing C. albicans, M. tuberculosis, Hepatitis B and C viruses, HIV, prions, 
Influenza, Cytomegalovirus (CMV), Epstein Barr virus (EBV), Herpes simplex virus 
(HSV). These aerosols are inhaled and they contaminate surfaces. Some studies have 
shown that HIV positive patients’ saliva contain HIV (Liuzzi et al., 1997)). The quantity 
of HIV in saliva depends on the blood viral load and the therapeutic status of patient 
(Liuzzi et al., 2000; Shepard et al., 2000). Therefore, sterilization and disinfection of any 
item that comes in contact with saliva is also important. Although the metal instruments 
are heat sterilized, some devices such as dental X-ray films, impression materials and 
prosthesis cannot be heat sterilized. An effective sterilant and surface disinfectant is a 
must in this situation. In this study, effect of two chlorinated disinfectants against three 
major dental setting contaminants such as S. mutans, M. tuberculosis and Hepatitis B were 
studied. The results showed that chlorine dioxide and NaDCC both killed all three 
organisms within 30 seconds. These results suggest that both these disinfectants can be 
used as sterilants and surface disinfectants in dental settings. Chlorine dioxide containing 
Aseptrol® particularly can be used on metal because it is noncorrosive. Use of Presept® in 
decontamination of dental X-ray films and use of Aseptrol® in decontamination of 
impression material have been studied (Coogan et al., 2004; Rweyndela et al., 2008), 
showing similar results to the ones shown in this study. Studies have shown the use of 
chlorine dioxide in plaque control (Nishikiori et al., 2008; Paraskevas et al., 2008) with no 
adverse effect on oral tissues and biofilm control in waterlines of dental units (Wirthlin 
and Marshall, 2001). Chlorine dioxide is a safe and clinically effective option in the 
management of chronic atrophic candidiasis. It can be used both as a topical antiseptic and 
for soaking dentures overnight after they have been removed from the mouth (Mohammad 
et al., 2004). 
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4.6 IMPLICATION OF SHELF-LIFE STUDY RESULTS 
 
Although manufacturers of chlorinated compounds recommend daily preparation of 
solutions, our results showed that Presept®, as well as Aseptrol® solutions can be effective 
for greater than 37 and 27 days respectively. This result has financial implication because 
leftover disinfectant can be utilized. It can also save time in daily preparation of 
disinfectant solution. Similar results were found by Rutala et al., (1998). They also 
showed that brown screw cap bottles were ideal for storage of chlorinated disinfectants.  
 
4.7 SAFETY OF CHLORINATED COMPOUNDS  
 
The efficacy, ‘user-friendliness and surface compatibility of a disinfectant should be 
established before use. Some disinfectants are irritant to the skin, eyes and respiratory tract 
and suitable personal protective equipments have to be worn. Due to concerns about the 
occupational safety of cleaning employees using sodium dichloroisocyanurate, Van Laer 
et al., (2008) conducted a small test to evaluate the concentration of chlorine in the air 
while cleaning employees disinfected a patient’s room and they concluded that there is no 
occupational hazard for cleaning employees while performing decontamination procedure 
with a solution containing 4,500 ppm free chlorine made from sodium 
dichloroisocyanurate dehydrate tablets.  Above study showed that it is safe to use 
chlorine-releasing disinfectants. A study has shown the safety of chlorine dioxide on 
gingival fibroblasts (Nishikiori et al., 2008). However, the safety of chlorine dioxide was 
not part of the scope of this study. 
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4.8 TECHNICAL DIFFICULTIES AND POSSIBLE SHORTCOMINGS 
A  
Shelf-life study for Hepatitis B Virus was not performed because the COBAS® 
Ampliprep/ COBAS® Taqman® HBV Test, which quantitates HBV viral DNA is very 
costly and the study funds were exhausted.  
B 
The growth incubation time for Mycobacteria ideally is 4-6 weeks. In shelf-life study 
some of the results were read after 4-5 weeks due to time constraints and due dates for 
completion of the study. 
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CHAPTER 5: CONCLUSION 
 
 
 
In conclusion, this study has shown that Aseptrol®, a slow release chlorine dioxide 
formula at 48ppm and 24ppm and chlorine releasing sodium dichloroisocyanurate 
containing disinfectant, Presept® at 10 000ppm are bactericidal, viricidal, 
mycobactericidal at 30 seconds contact time period and at 2 to 3 minutes, sporicidal in the 
presence of organic material. Prepared disinfectants solutions of Aseptrol® and Presept®, if 
stored in screw cap bottles, can be effective for 27 and greater than 37 days respectively. 
Aseptrol® can be used on metal instruments because of its noncorrosive property.  
Our preliminary results showed that both disinfectants have potentials to be used in 
medical and dental settings for intermediate to high-level disinfection and as sterilants. 
However, further relevant testing would be required. 
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CHAPTER 6: APPENDICES 
 
 
APPENDIX A   
 
Composition and preparation of media 
 
1. Blood Agar 
Oxoid Columbia agar base              100g 
Demineralised water               2.5 L 
 
These are well mixed, autoclaved at 121oC for 30 minutes and then cooled at 50oC. 
With aseptic precautions the following is added. 
 
Sterile citrated horse blood (at room temperature) 100ml 
pH is adjusted to 7.5 and aseptically distributed in sterile petri dishes. 
 
2. Tryptone Soy Agar 
Tryptone soy agar     40 g 
Distilled water      1 L 
The ingredients should be dissolved and autoclaved at 121oC for 15 minutes. 
pH       7.0 
Aseptically distributed in sterile petri dishes 
 
3. Sabouraud Dextrose Agar 
Sabouraud agar     60 g 
Distilled water      1 L 
The ingredients should be dissolved and autoclaved at 121oC for 15 minutes. 
pH       7.0 
Aseptically distributed in sterile petri dishes 
 
4. Middlebrook 7H10 Agar (BD 262710) with 
Middlebrook OADC Enrichment (BD 212240)  
Middlebrook 7H10     19g 
 Glycerol      5.0ml  
 OADC Enrichment     100ml 
 deionised water     900ml 
 
5. Neutralizing fluid 
Sodium chloride     2.25 g 
Potassium chloride      0.105 g 
Calcium chloride     0.12 g 
Sodium bicarbonate     0.05 g 
Distilled water      1.0 L 
Sodium thiosulphate     5.0 g 
Tween 80      5.0 ml 
The ingredients should be dissolved and autoclaved at 121oC for 15 minutes. 
pH       7.0 
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       6. BACTEC Mycobacteria Growth Indicator Tube (MGIT) 
MGIT contains 110µl of fluorescent indicator and 7 ml of broth. The indicator 
contains Tris 4,7-diphenyl-1, 10-phenanthroline ruthenium chloride pentahydrate 
in a silicone rubber base. The tubes are flushed with 10% CO2 and capped with 
polypropylene caps. 
 
Approximate formula per litre of purified water: 
 Modified Middlebrook 7H9 Broth base  5.9g 
 Casein peptone      1.25g 
 
MGIT Growth supplement contains 15 ml Middlebrook OADC enrichment 
 
Approximate formula per litre of purified water: 
 Bovine albumin     50g 
 Catalase      0.03g 
 Dextrose      20g 
 Oleic acid      0.1g 
 Polyoxyethylene stearate (POES)   1.1g 
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APPENDIX B  
 
Preparation of solutions for Hepatitis B Virus study 
(COBAS® Ampliprep/COBAS® TaqMan® HBV Test) 
 
 
1. HBV CS1 (HBV magnetic glass particle reagent cassette) 
 Magnetic glass particles 
 Isopropanol      93% 
 
2. HBV CS2 (HBV lysis reagent cassette) 
 Sodium citrate dehydrate 
 Guanidine thiocyanate    42.5% 
Polydocanol      < 14% 
Dithiothreitol      0.9% 
 
3. HBV CS3 HBV multi-reagent cassette containing: 
Pase (Proteinase solution) 
 Tris buffer 
 EDTA       < 0.05% 
 Calcium chloride 
 Calcium acetate 
 proteinase       ≤ 7.8%                
 Glycerol 
EB (Elution buffer) 
 Tris-base buffer 
 Methylparaben     0.2% 
 
4. HBV CS4 HBV test-specific reagent cassette containing: 
HBV QS (HBV quantitation standard) 
 Tris-HCL buffer 
 EDTA 
 Poly Ra RNA (synthetic)    <0.005% 
 non-infectious, linearized, double-stranded plasmid DNA containing     
             an insert  with HBV primer binding sequence and a unique probe binding     
             region       < 0.001% 
 sodium azide      0.05% 
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5. HBV MIX (HBV master mix) 
 Tricine buffer 
 Potassium acetate 
 Potassium hydroxide 
 sodium azide      0.09% 
Glycerol 
 ATP, CTP, GTP, UTP    <0.04% 
 upstream and downstream HBV primers  <0.003% 
 Oligonucleotide aptamer    <0.003% 
fluorescent-labelled oligonocleotide probes specific for HBV and the HBV QS 
standard      <0.003% 
Z05 DNA polymerase (microbial)   < 0.05% 
AmpErase (uracil-N-glycosylase) enzyme(microbial) < 0.1% 
  
6. HBV Mn2+ (HBV Manganese solution) 
manganese acetate     <0.5% 
Glacial acetic acid 
sodium azide      0.09% 
 
7. HBV H (+) C (HBV high positive control) 
linearized, double stranded plasmid DNA containing HBVsequences 
Negative human plasma- non-reactive by tests to antibody to HBC, HIV- 1/2, HIV 
p24        <0.001% 
Antigen and HBsAG; HIV-1 RNA and HBV DNA not detectable by PCR 
methods. 
proclin® 300 preservative    0.1% 
 
8. HBV L (+) C (HBV low positive control) 
linearized, double stranded plasmid DNA containing HBV sequences 
Negative human plasma- non-reactive by tests to antibody to HBC, HIV- 1/2, HIV 
p24       <0.001% 
Antigen and HBsAG; HIV-1 RNA and HBV DNA not detectable by PCR 
methods. 
proclin® 300 preservative    0.1% 
 
9. CTM (-) C (COBAS® TaqMan® negative control human plasma) 
Negative human plasma- non-reactive by tests to antibody to HBC, HIV- 1/2, HIV 
p24  
Antigen and HBsAG; HIV-1 RNA and HBV DNA not detectable by PCR 
methods. 
proclin® 300 preservative    0.1% 
 
10. PG WR (COBAS® Ampliprep/COBAS®  TaqMan® wash reagent) 
 Sodium citrate dehydrate 
N-Methylisothiazolone-HCL    <0.1% 
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APPENDIX C 
Result printout from AMPLILINK® for HBV 
Figure C1 Negative control result printout from AMPLILINK® for HBV 
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Figure C2 Low positive control result printout from AMPLILINK® for HBV 
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Figure C3 High positive control result printout from AMPLILINK® for HBV 
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Figure C4 Sample of negative result printout from AMPLILINK® for HBV 
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Figure C5 Ethical clearance 1 
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Figure C6 Ethical clearance 2 
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